Overview

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

Status:
Recruiting

Trial end date:
2022-02-27

Target enrollment:

Participant gender:

Summary

This study examines the sensitivity of functional MRI to detect brain changes caused by donepezil HCL (a cholinesterase inhibitor) in healthy older adults at genetic risk for Alzheimer's Disease.

Phase:

Phase 4

Details

Lead Sponsor:

The Cleveland Clinic

Collaborator:

National Institute on Aging (NIA)

Treatments:

Donepezil